Mark Holm, MD
Endocrinology, Diabetes & Metabolism · Saint Cloud, MNNPI 1831189240
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $274,442 of the $317,711 with a category attached, or 86.4%. 9 manufacturers reported payments, led by Novo Nordisk at 50.2% of the total. Reporting peaked in 2019 at $119,544 and has fallen 61.6% since, to $45,944 in 2025. Among endocrinology, diabetes & metabolism clinicians in MN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 353 payments — averaging $900.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$159K
- Sanofi-aventis U.S. LLC$55K
- Merck$35K
- AstraZeneca$28K
- Bayer$20K
- Johnson & Johnson$20K
- plus $349 from 3 others
What the payments were for
- Consulting fees$9300%
- Speaking & faculty fees$274,44286%
- Travel & lodging$38,43412%
- Food & beverage$3,7711%
- Education$1340%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 166 | $159,333 |
| Sanofi-aventis U.S. LLC | 58 | $55,469 |
| Merck | 34 | $34,690 |
| AstraZeneca | 31 | $27,767 |
| Bayer | 37 | $20,211 |
| Johnson & Johnson | 23 | $19,891 |
| Boehringer Ingelheim | 2 | $191 |
| GSK | 1 | $83 |
| Amarin Pharma, Inc. | 1 | $75 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$317,711 in reported general payments places this provider in the 95th percentile of 120 endocrinology, diabetes & metabolism providers in Minnesota.
See all endocrinology, diabetes & metabolism providers in Minnesota →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 255 | $403,178 |
| FarxigaDapagliflozin Propanediol | 137 | $144,276 |
| KerendiaFinerenone | 76 | $80,188 |
| JardianceEmpagliflozin | 56 | $79,690 |
| RybelsusSemaglutide | 39 | $59,524 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 57 | $52,702 |
| Teriparatide | 11 | $46,688 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 24 | $35,235 |
| CyclosetBromocriptine Mesylate | 13 | $24,186 |
| Victoza 3-PakLiraglutide | 18 | $20,174 |
| InvokanaCanagliflozin | 11 | $17,329 |
| Icosapent Ethyl | 24 | $16,246 |
| Novolog FlexpenInsulin Aspart | 39 | $15,721 |
| Humalog Kwikpen U-100Insulin Lispro | 37 | $13,934 |
| Tresiba Flextouch U-100Insulin Degludec | 24 | $9,520 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $159,333 | $462,701294 claims |
| AstraZenecaFarxiga | $27,767 | $144,276137 claims |
| BayerKerendia | $20,211 | $80,18876 claims |
| Boehringer IngelheimJardiance | $191 | $79,69056 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $55,469 | $35,23524 claims |
| Johnson & JohnsonInvokana | $19,891 | $17,32911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 120 endocrinology, diabetes & metabolism providers in Minnesota.
Other endocrinology, diabetes & metabolism in Saint Cloud
- Richard BergenstalSt Louis Park$595K
- Farha KhanCoon Rapids$349K
- Marjorie Ann MalbasRochester$222K
- Anders CarlsonSt Louis Park$163K
- Maria CaramoriMinneapolis$147K
- Irina BancosRochester$114K
- Sidney JonesChaska$67K
- Maria CastroRochester$63K
- Marius StanRochester$59K
- Matthew DrakeRochester$41K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.